Literature DB >> 23806236

Expanding research to provide an evidence base for nutritional interventions for the management of inborn errors of metabolism.

Kathryn M Camp1, Michele A Lloyd-Puryear, Lynne Yao, Stephen C Groft, Melissa A Parisi, Andrew Mulberg, Rashmi Gopal-Srivastava, Stephen Cederbaum, Gregory M Enns, Abby G Ershow, Dianne M Frazier, John Gohagan, Cary Harding, R Rodney Howell, Karen Regan, Peter W Stacpoole, Charles Venditti, Jerry Vockley, Michael Watson, Paul M Coates.   

Abstract

A trans-National Institutes of Health initiative, Nutrition and Dietary Supplement Interventions for Inborn Errors of Metabolism (NDSI-IEM), was launched in 2010 to identify gaps in knowledge regarding the safety and utility of nutritional interventions for the management of inborn errors of metabolism (IEM) that need to be filled with evidence-based research. IEM include inherited biochemical disorders in which specific enzyme defects interfere with the normal metabolism of exogenous (dietary) or endogenous protein, carbohydrate, or fat. For some of these IEM, effective management depends primarily on nutritional interventions. Further research is needed to demonstrate the impact of nutritional interventions on individual health outcomes and on the psychosocial issues identified by patients and their families. A series of meetings and discussions were convened to explore the current United States' funding and regulatory infrastructure and the challenges to the conduct of research for nutritional interventions for the management of IEM. Although the research and regulatory infrastructure are well-established, a collaborative pathway that includes the professional and advocacy rare disease community and federal regulatory and research agencies will be needed to overcome current barriers.
Copyright © 2013. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  ACA; CDER; CER; CTSA; Center for Drug Evaluation and Research; Clinical and Translational Science Award; Comparative Effectiveness Research; DSHEA; Dietary Supplement Health and Education Act; Dietary supplements; Eunice Kennedy Shriver National Institute of Child Health and Human Development; FD&C Act; FDA; Federal Food, Drug and Cosmetic Act; Food and Drug Administration; GPCI; GRDR; Genetic; Genetics in Primary Care Institute; Global Rare Disease Patient Registry and Data Repository; HIE; HRSA; Health Resources and Services Administration; IEM; IRB; Inborn errors of metabolism; LTFU; Medical foods; NBSTRN; NCATS; NICHD; NIH; National Center for Advancing Translational Sciences; National Institutes of Health; Newborn Screening Translational Research Network; Newborn screening; ODA; ODS; OOPD; ORDR; Office of Dietary Supplements; Office of Orphan Product Development; Office of Rare Diseases Research; Orphan Drug Act; PAH; PCMH; PCORI; PHE; PKU; Patient Protection and Affordable Care Act; Patient-Centered Outcomes Research Institute; RDCRN; RDP; Rare Diseases Clinical Research Network; Rare Diseases Program; Rare diseases; health information exchange; inborn errors of metabolism; institutional review board; long-term follow-up; patient-centered medical home; phenylalanine; phenylalanine hydroxylase; phenylketonuria

Mesh:

Year:  2013        PMID: 23806236      PMCID: PMC4131198          DOI: 10.1016/j.ymgme.2013.05.008

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  22 in total

Review 1.  How to improve R&D productivity: the pharmaceutical industry's grand challenge.

Authors:  Steven M Paul; Daniel S Mytelka; Christopher T Dunwiddie; Charles C Persinger; Bernard H Munos; Stacy R Lindborg; Aaron L Schacht
Journal:  Nat Rev Drug Discov       Date:  2010-02-19       Impact factor: 84.694

Review 2.  A review finds that multicenter studies face substantial challenges but strategies exist to achieve Institutional Review Board approval.

Authors:  Sarah M Greene; Ann M Geiger
Journal:  J Clin Epidemiol       Date:  2006-03-15       Impact factor: 6.437

3.  Graduate medical education, 2008-2009.

Authors:  Sarah E Brotherton; Sylvia I Etzel
Journal:  JAMA       Date:  2009-09-23       Impact factor: 56.272

Review 4.  Grinding to a halt: the effects of the increasing regulatory burden on research and quality improvement efforts.

Authors: 
Journal:  Clin Infect Dis       Date:  2009-08-01       Impact factor: 9.079

Review 5.  Psychosocial aspects of PKU: hidden disabilities--a review.

Authors:  J K Gentile; A E Ten Hoedt; A M Bosch
Journal:  Mol Genet Metab       Date:  2010       Impact factor: 4.797

6.  Two years of PKU testing in California. The role of the laboratory.

Authors:  G C Cunningham
Journal:  Calif Med       Date:  1969-01

7.  Clinical research for rare disease: opportunities, challenges, and solutions.

Authors:  Robert C Griggs; Mark Batshaw; Mary Dunkle; Rashmi Gopal-Srivastava; Edward Kaye; Jeffrey Krischer; Tan Nguyen; Kathleen Paulus; Peter A Merkel
Journal:  Mol Genet Metab       Date:  2008-11-13       Impact factor: 4.797

8.  A diversified approach for PKU treatment: routine screening yields high incidence of psychiatric distress in phenylketonuria clinics.

Authors:  Barbara K Burton; Lauren Leviton; Hazel Vespa; Hilary Coon; Nicola Longo; Bridget D Lundy; Maria Johnson; Andrew Angelino; Ada Hamosh; Deborah Bilder
Journal:  Mol Genet Metab       Date:  2012-11-15       Impact factor: 4.797

9.  Standards of professional practice for genetic metabolic dietitians.

Authors:  Rani H Singh; Melissa M Kaczmarczyk
Journal:  Genet Med       Date:  2008-04       Impact factor: 8.822

10.  Mapping gene associations in human mitochondria using clinical disease phenotypes.

Authors:  Curt Scharfe; Henry Horng-Shing Lu; Jutta K Neuenburg; Edward A Allen; Guan-Cheng Li; Thomas Klopstock; Tina M Cowan; Gregory M Enns; Ronald W Davis
Journal:  PLoS Comput Biol       Date:  2009-04-24       Impact factor: 4.475

View more
  5 in total

Review 1.  Inborn errors of metabolism identified via newborn screening: Ten-year incidence data and costs of nutritional interventions for research agenda planning.

Authors:  Bradford L Therrell; Michele A Lloyd-Puryear; Kathryn M Camp; Marie Y Mann
Journal:  Mol Genet Metab       Date:  2014-07-16       Impact factor: 4.797

Review 2.  The changing landscape of clinical trials for mitochondrial diseases: 2011 to present.

Authors:  Delia Khayat; Tracie L Kurtz; Peter W Stacpoole
Journal:  Mitochondrion       Date:  2019-10-25       Impact factor: 4.160

Review 3.  Current experience in testing mitochondrial nutrients in disorders featuring oxidative stress and mitochondrial dysfunction: rational design of chemoprevention trials.

Authors:  Giovanni Pagano; Annarita Aiello Talamanca; Giuseppe Castello; Mario D Cordero; Marco d'Ischia; Maria Nicola Gadaleta; Federico V Pallardó; Sandra Petrović; Luca Tiano; Adriana Zatterale
Journal:  Int J Mol Sci       Date:  2014-11-05       Impact factor: 5.923

4.  A critical reappraisal of dietary practices in methylmalonic acidemia raises concerns about the safety of medical foods. Part 1: isolated methylmalonic acidemias.

Authors:  Irini Manoli; Jennifer G Myles; Jennifer L Sloan; Oleg A Shchelochkov; Charles P Venditti
Journal:  Genet Med       Date:  2015-08-13       Impact factor: 8.822

5.  Development of newborn screening connect (NBS connect): a self-reported patient registry and its role in improvement of care for patients with inherited metabolic disorders.

Authors:  Yetsa Osara; Kathryn Coakley; Aishwarya Devarajan; Rani H Singh
Journal:  Orphanet J Rare Dis       Date:  2017-07-19       Impact factor: 4.123

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.